Defence Therapeutics Appoints Former Biogen Executive Dr. John Beaver to Board of Directors
核心洞察
Defence Therapeutics (搜索) has appointed Dr. John Beaver, former Vice President and Head of Global Biomarker Discovery & Development at Biogen, to its Board of Directors.
Dr. Beaver brings over two decades of leadership experience from major pharmaceutical companies including Biogen, AbbVie (搜索), and GlaxoSmithKline, with expertise in translational medicine and biomarker development.
During his tenure at Biogen, Dr. Beaver led biomarker development activities supporting approximately 48 pipeline programs and contributed to FDA accelerated approvals in Alzheimer's disease (搜索) and ALS (搜索).
Defence Therapeutics (搜索) Inc., a publicly traded biotechnology company focused on precision intracellular drug delivery, announced the appointment of Dr. John Beaver to its Board of Directors. The Montreal-based company made the announcement on June 3, 2026, highlighting Dr. Beaver's extensive pharmaceutical industry experience spanning more than two decades.
Extensive Pharmaceutical Leadership Background
Dr. Beaver brings significant leadership experience from major biopharmaceutical organizations, including senior positions at Biogen, AbbVie (搜索), and GlaxoSmithKline. His expertise encompasses translational medicine, biomarker discovery and development, and clinical pharmacology, providing deep understanding of therapeutic advancement and strategic development within global pharmaceutical organizations.
Most recently, Dr. Beaver served as Vice President and Head of Global Biomarker Discovery & Development at Biogen, where he led global biomarker and translational development activities supporting approximately 48 pipeline programs. During his tenure at Biogen, he contributed to biomarker-driven development strategies associated with industry-first FDA accelerated approvals in Alzheimer's disease (搜索) and ALS (搜索), while serving on several R&D leadership, governance, and partnership committees.
Career Progression Across Leading Organizations
Prior to his role at Biogen, Dr. Beaver held senior leadership positions at AbbVie (搜索), where he served as Head of Translational Imaging and was recognized as a Volwiler Research Fellow for his scientific contributions. His earlier career included positions as Senior Imaging Scientist at GlaxoSmithKline's Clinical Imaging Centre at Imperial College London's Hammersmith Hospital campus and Director of Imaging at Maccine in Singapore. He also conducted human brain imaging research as a postdoctoral fellow with the UK Medical Research Council at the University of Cambridge.
Currently, Dr. Beaver serves as Co-Founder and Chief Executive Officer of a stealth-mode biotechnology company based in the Greater Boston area, where he leverages his experience in translational science, biomarker innovation, and strategic drug development to advance next-generation therapeutic approaches.
Strategic Value for Defence's Growth
"We are very proud to welcome Dr. John Beaver to Defence's Board of Directors," said Sébastien Plouffe, CEO of Defence Therapeutics (搜索). "John extensive pharmaceutical industry experience will be highly valuable as Defence continues advancing its ACCUM® (搜索) platform and expanding its development and partnership activities."
Dr. Beaver expressed enthusiasm about joining the company during this growth phase. "I am excited to join Defence Therapeutics (搜索)' Board of Directors and support the Company during this important stage of growth," he said. "Defence's ACCUM® (搜索) technology has the potential to significantly enhance intracellular delivery and unlock new possibilities for next-generation therapeutics. I look forward to supporting the Company's strategic growth and helping strengthen its strategic and pharmaceutical partnership initiatives."
Compensation and Platform Development
Defence Therapeutics (搜索) has granted Dr. Beaver 150,000 incentive stock options in accordance with the company's omnibus incentive plan. The options are vested immediately and exercisable at 60 cents per share for five years from the grant date.
The company is actively advancing its proprietary ACCUM® (搜索) platform across multiple therapeutic applications, including antibody-drug conjugates (ADCs) and radiopharmaceuticals. The platform aims to improve intracellular delivery, therapeutic efficacy, and overall treatment outcomes. Defence Therapeutics (搜索) focuses on making cancer (搜索) treatment more effective and safer by enhancing the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies.